NASDAQ:OPXA »

• 
  Company News » Opexa Amends Agreement with Merck Serono and Receives Additional $3 Million Payment to Support Ongoing Development of Tcelna(R) for Multiple Sclerosis

  Business Wire - March 9, 2015, 11:02 GMT

  Opexa Therapeutics, Inc. (NASDAQ:OPXA) , a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has amended its option and license agreement with Merck Serono (a division of Merck, Darmstadt, Germany) and will receive a $3 million payment. The payment provides support for the ongoing Phase

  Read full story »
• 
  Company News » Opexa Therapeutics, Inc. Announces Record Date and Subscription Price for Rights Offering

  Business Wire - February 25, 2015, 22:11 GMT

  Opexa Therapeutics, Inc. (NASDAQ:OPXA) , a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has set 5:00 p.m. Eastern Time on March 13, 2015 as the record date for its upcoming rights offering. Opexa intends to issue subscription rights to purchase units, composed of

  Read full story »
• 
  Company News » Opexa Therapeutics Reports Year End 2014 Financial Results and Provides Corporate Update

  Business Wire - February 23, 2015, 11:06 GMT

  Opexa Therapeutics, Inc. (NASDAQ:OPXA) , a biopharmaceutical company developing personalized immunotherapies including multiple sclerosis (MS) and neuromyelitis optica (NMO), today reported financial results for the year ended December 31, 2014 and provided an update on the Company’s recent corporate developments. 2014 and early 2015 Operational Highlights: Completed enrollment in the Abili-T Phase 2b clinical trial

  Read full story »
• 
  Company News » Opexa Therapeutics, Inc. Files Registration Statement for Rights Offering

  Business Wire - January 28, 2015, 11:06 GMT

  Opexa Therapeutics, Inc. (NASDAQ:OPXA) , a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has filed a registration statement with the Securities and Exchange Commission (SEC) for a proposed rights offering of subscription rights to purchase units comprised of a share of Opexa common

  Read full story »
• 
  Company News » Opexa Therapeutics Selected as One of the “Top 10 Advanced Therapy Projects to Watch”

  Business Wire - November 18, 2014, 14:11 GMT

  Opexa Therapeutics, Inc. (NASDAQ:OPXA) , a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced Opexa has been named one of the “Top 10 Advanced Therapy Projects to Watch” by Elsevier Business Intelligence for the second consecutive year. As part of this recognition, Neil K. Warma,

  Read full story »
• 
  Company News » Opexa Therapeutics CEO Invited to Join Personalized Medicine Panel at New York CEO Conference

  Business Wire - November 11, 2014, 14:03 GMT

  Opexa Therapeutics, Inc. (NASDAQ:OPXA) , a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, Opexa’s President and Chief Executive Officer, has been invited as a panel member to participate in the New York CEO Conference. The event will take place November

  Read full story »
• 
  Company News » Opexa Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update

  Business Wire - November 6, 2014, 21:06 GMT

  Opexa Therapeutics, Inc. (NASDAQ:OPXA) , a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today reported financial results for the third quarter ended September 30, 2014 and provided an overview of the Company’s recent corporate developments. Recent highlights include: Operational Highlights: Opexa announced it had initiated early

  Read full story »
• 
  Company News » Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Third Quarter 2014 Financial Results

  Business Wire - November 5, 2014, 14:03 GMT

  Opexa Therapeutics, Inc. (NASDAQ:OPXA) , a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the three months ended September 30, 2014 after the close of trading on Thursday, November 6th. The Company will also conduct a conference

  Read full story »
• 
  Company News » Opexa Therapeutics Supports National Multiple Sclerosis Society and Walk MS

  Business Wire - October 22, 2014, 13:07 GMT

  Opexa Therapeutics, Inc. (NASDAQ:OPXA) , a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced its partnership with the National Multiple Sclerosis Society, Lone Star Chapter, as a sponsor of the nonprofit’s annual Houston area Walk MS fundraisers for the fourth consecutive year. Opexa is supporting the

  Read full story »
• 
  Company News » Opexa Therapeutics to Present at Cleveland Clinic’s 12th Annual Medical Innovation Summit

  Business Wire - October 20, 2014, 13:08 GMT

  Opexa Therapeutics, Inc. (NASDAQ:OPXA) , a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that Neil K. Warma, the Company’s President and Chief Executive Officer, has been invited to present at the Cleveland Clinic’s 12th Annual Medical Innovation Summit, taking place October 26-29, 2014, in

  Read full story »